Investment Rating - The industry investment rating is "Buy" with a previous rating of "Buy" as well [7]. Core Viewpoints - The report emphasizes focusing on individual stocks rather than sector allocation due to three main reasons: (1) AI application stock price drivers are primarily liquidity spillover; (2) AI computing power requires more catalysts, indicating a current state of stock competition rather than overall growth; (3) the overall industry valuation faces certain pressures [10][12]. - Current viewpoints suggest: (1) Given absolute valuation levels and changes in market risk appetite, it is not advisable to be overly aggressive at the sector level; (2) Focus on undervalued stocks with a high probability of marginal changes in Q1; (3) Maintain positive attention on Hongmeng, Xinchuang, and smart vehicles [10][12]. Summary by Relevant Sections Key Stocks - **Unisplendour**: Strong expectations for network switching equipment and server segments, with a current PE of 21 times for 2025 [11][14]. - **Newland**: Stable traditional business with early layout in network certificate encryption systems, with a PE of 13 times for 2025 [14]. - **Kingsoft Office**: Expected to benefit from the solidification of its leading position in office software and the ongoing AI application rollout, with a PS of approximately 19 times and PE of 64 times for 2025 [18][19]. - **ZWSOFT**: Anticipated revenue growth as the proportion of educational clients decreases, with a PS of 8 times for 2025 [19]. - **Cambricon**: Recognized as a flagbearer in hard technology, with a PS of 74 times for 2025 [19]. - **Fourth Paradigm**: Benefiting from strong demand for AI application development tools, with a PS of 4 times for 2025 [23]. - **Kingdee International**: Successful cloud transformation with a PS of 3.5 times for 2025 [24]. - **Vertex Software**: Expected to benefit from the upcoming core trading system tenders, with a PE of 24 times for 2025 [25]. Market Performance - The computer industry index fell by 12.70% over the past week, ranking 30th among all industries, while the Shanghai Composite Index decreased by 5.55% [26].

Xml [Table_Title] 国防军工行业 十四五收官景气上行可期，板块中长期成长曲线清晰 [Table_Summary] 核心观点： [Table_Page] 投资策略周报|国防军工 证券研究报告 | [Table_Grade] 行业评级 | 买入 | | --- | --- | | 前次评级 | 买入 | | 报告日期 | 2025-01-05 | | [分析师： Table_Author]孟祥杰 | | | --- | --- | | | SAC 执证号：S0260521040002 | | | SFC CE No. BRF275 | | | 010-59136693 | | | mengxiangjie@gf.com.cn | | 分析师： | 吴坤其 | | | SAC 执证号：S0260522120001 | | | SFC CE No. BRT139 | | | 010-59133689 | | | wukunqi@gf.com.cn | | 分析师： | 邱净博 | | | SAC 执证号：S0260522120005 | | | 010-59136685 | | | qiujingbo ...

[Table_Page] 投资策略周报|农林牧渔 证券研究报告 [TAblE_TitlE] 农林牧渔行业 如何看 24 年宠物医疗行业发展趋势 -30% -18% -6% 6% 18% 30% 01/24 03/24 05/24 08/24 10/24 01/25 农林牧渔 沪深300 | [分析师： TAblE_Author 钱浩] | | --- | | SAC 执证号：S0260517080014 | | SFC CE No. BND274 | | 021-38003634 | | shqianhao@gf.com.cn | | 分析师： 周舒玥 | | SAC 执证号：S0260523050002 | | 021-38003537 | | zhoushuyue@gf.com.cn | | 分析师： 李雅琦 | | SAC 执证号：S0260524080006 | | 021-68827265 | | liyaqi@gf.com.cn | | 请注意，周舒玥,李雅琦并非香港证券及期货事务监察委员 | | 会的注册持牌人，不可在香港从事受监管活动。 | | --- | [TAblE_ 相关研究： DoCR ...

[Table_Page] 投资策略周报|有色金属 证券研究报告 | [Table_Title] 金属及金属新材料行业 | | --- | 黄金配置价值凸显 [Table_Summary] 核心观点： [Table_Gr ade] 行业评级 买入 前次评级 买入 报告日期 2025-01-05 [Table_PicQuote] 相对市场表现 重点公司估值和财务分析表 -20% -10% 0% 10% 20% 30% 01/24 03/24 05/24 08/24 10/24 01/25 有色金属 沪深300 | [分析师： Table_Author]宫帅 | | | --- | --- | | | SAC 执证号：S0260518070003 | | | SFC CE No. BOB672 | | | 010-59136627 | | | gongshuai@gf.com.cn | | 分析师： | 王乐 | | | SAC 执证号：S0260523050004 | | | 021-38003617 | | | wangle@gf.com.cn | | 分析师： | 陈琪玮 | | | SAC 执证号：S026 ...

[Table_Page] 投资策略周报|通信 证券研究报告 [Table_Title] 通信行业 微软数据中心资本开支同比大幅提升，继续看好算力基建产业链 [Table_Summary] 核心观点： | [Table_Grade] 行业评级 | 买入 | | --- | --- | | 前次评级 | 买入 | | 报告日期 | 2025-01-05 | [Table_PicQuote] 相对市场表现 [分析师： Table_Author]韩东 -20% -7% 6% 18% 31% 44% 01/24 03/24 05/24 08/24 10/24 01/25 通信 沪深300 | SAC 执证号：S0260523050005 | | | --- | --- | | 021-38003776 | | | gfhandong@gf.com.cn | | | 分析师： | 戎志强 | | SAC 执证号：S0260523090001 | | | 021-38003535 | | | rongzhiqiang@gf.com.cn | | | 分析师： | 王亮 | | SAC 执证号：S0260519060001 ...

Investment Rating - The report assigns a "Buy" rating to the company with a current price of 58.02 CNY and a fair value of 69.64 CNY [3]. Core Views - The company is a high-tech enterprise focused on providing testing equipment for semiconductor, display, and new energy sectors, leveraging vertical integration capabilities to break overseas technology monopolies and maintain industry leadership in panel display testing [10][17]. - The semiconductor measurement equipment segment is experiencing continuous breakthroughs, with significant orders in advanced processes and a total order backlog of approximately 1.767 billion CNY [10][17]. - The display sector is expected to benefit from the construction of AMOLED 8.6 generation lines and the innovation cycle in consumer electronics, with major projects from companies like BOE and Visionox [10][17]. - The company forecasts revenue growth from 29.25 billion CNY in 2024 to 43.80 billion CNY in 2026, with net profit expected to rise from 2.13 billion CNY to 5.77 billion CNY during the same period [10][17]. Summary by Sections Company Overview - The company has established a comprehensive service provider role in the semiconductor, display, and new energy industries, focusing on testing equipment [10][17]. - It has expanded its product matrix significantly, with a revenue share of 71.9% from display testing, 16.3% from semiconductors, and 9.9% from new energy in 2023 [19][20][31]. Semiconductor Sector - The semiconductor testing market is divided into front-end and back-end categories, with front-end measurement holding a larger value share [41]. - The company is a leading player in the domestic semiconductor testing equipment market, with a focus on both front-end and back-end testing solutions [63]. Display Sector - The company’s display testing equipment includes systems for LCD, OLED, and Mini/Micro-LED technologies, benefiting from the growth in consumer electronics [19][20]. - The construction of new AMOLED production lines is expected to drive demand for the company's products [10][17]. New Energy Sector - The company is involved in the production and testing of lithium battery equipment, with strategic partnerships to enhance its competitive edge in this sector [20][21]. Financial Forecasts - Revenue is projected to recover from 24.29 billion CNY in 2023 to 29.25 billion CNY in 2024, with net profit expected to increase significantly from 150 million CNY to 213 million CNY in the same period [2][10]. - The company anticipates a steady increase in EPS from 0.54 CNY in 2023 to 2.10 CNY by 2026 [2][10].

[Table_Page] 跟踪研究|酒店餐饮 证券研究报告 [Table_Title] 君亭酒店（301073.SZ） 宣布进军加盟，向规模化目标迈进 [Table_Summary] 核心观点： 盈利预测： | [Table_Finance] | 2022A | 2023A | 2024E | 2025E | 2026E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 342 | 534 | 665 | 810 | 974 | | 增长率（ % ） | 23.2% | 56.2% | 24.6% | 21.8% | 20.3% | | EBITDA（百万元） | 157 | 250 | 230 | 302 | 362 | | 归母净利润（百万元） | 30 | 31 | 29 | 85 | 131 | | 增长率（ ） % | -19.4% | 2.6% | -5.1% | 193.9% | 54.0% | | EPS（元/股） | 0.18 | 0.16 | 0.15 | 0.44 | 0.67 | | 市盈率（P/E） | 389.44 | 14 ...

[Table_Page] 公司深度研究|有色金属 证券研究报告 | [Table_Title] 玉龙股份（601028.SH） | | --- | 黄金新秀，乘风起航 [Table_Summary] 核心观点： | Table_Invest] [公司评级 | 买入 | | --- | --- | | 当前价格 | 11.35 元 | | 合理价值 | 15.51 元 | | 报告日期 | 2025-01-03 | 基本数据 [Table_BaseInfo] | 总股本/流通股本（百万股） | 783.03/783.03 | | --- | --- | | 总市值/流通市值（百万元） | 8887.34/8887.34 | | 一年内最高/最低（元） | 15.88/7.11 | | 30 日日均成交量/成交额（百万） | 31.16/398.90 | | 近 3 个月/6 个月涨跌幅（%） | -21.56/-11.74 | [Table_PicQuote] 相对市场表现 [分析师： Table_Author]宫帅 SAC 执证号：S0260518070003 SFC CE No. BOB672 010-59 ...

[Table_Page] 公告点评|白酒Ⅱ 证券研究报告 [Table_Title] 贵州茅台（600519.SH） 2024 圆满收官，经营韧性显现 [Table_Summary] 核心观点： 请注意，符蓉并非香港证券及期货事务监察委员会的注册 持牌人，不可在香港从事受监管活动。 识别风险，发现价值 请务必阅读末页的免责声明 | DocReport] [Table_ 相关研究： | | | --- | --- | | 贵州茅台（600519.SH）:业 | 2024-10-27 | | 绩符合预期，稳步实现增长 | | | 目标 | | | 贵州茅台（600519.SH）:营 | 2024-08-09 | | 收略超预期，三年分红提信 | | | 心 | | | 贵州茅台（600519.SH）:营 | 2024-04-28 | | 收开门红，销售投入谋长远 | | | 盈利预测： | | | | | | | --- | --- | --- | --- | --- | --- | | [Table_Finance] | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业收 ...

Investment Rating - The report maintains a "Buy" rating for the company [9] Core Insights - The company announced that the NDA for the combination therapy of Savolitinib and Osimertinib for treating MET-amplified EGFR-mutant NSCLC has been accepted by the National Medical Products Administration and is under priority review [5] - The company plans to use the proceeds from the sale of its 45% stake in Shanghai Henlius Biotech for further development of its internal product pipeline, including a new generation ADC platform [5] - The estimated reasonable value of the company is HKD 41.35 per share, with projected net profits of USD 0.05 million, USD 0.20 million, and USD 0.74 million for the years 2024 to 2026 respectively [5] Financial Summary - Main revenue is projected to grow from USD 426 million in 2022 to USD 838 million in 2023, followed by a decline to USD 641 million in 2024 [3] - EBITDA is expected to improve from a loss of USD 361 million in 2022 to a profit of USD 78 million in 2023, with a forecasted loss of USD 7 million in 2024 [3] - The net profit attributable to shareholders is projected to turn from a loss of USD 361 million in 2022 to a profit of USD 101 million in 2023, and further to USD 5 million in 2024 [3] - The company’s EPS is expected to rise from -0.42 in 2022 to 0.12 in 2023, and reach 0.08 by 2026 [3] - The company’s ROE is projected to improve from -56.6% in 2022 to 13.6% in 2023, and reach 8.7% by 2026 [3]